Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Institute of Hematology & Blood Diseases Hospital, China
UNC Lineberger Comprehensive Cancer Center
St. Anna Kinderkrebsforschung
Rutgers, The State University of New Jersey
University Hospital Heidelberg
University of British Columbia
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center